ArticleOpen forum infectious diseases2026
Burden and Challenges in the Diagnosis and Treatment of Histoplasmosis Among Persons With Advanced HIV Disease in Uganda, 2025.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Data on the true burden of histoplasmosis in Uganda are limited, largely due to the scarcity of epidemiological studies. We aimed to describe the nationwide burden of histoplasmosis among persons with advanced HIV disease (AHD), highlighting the major challenges in diagnosis and treatment under routine HIV care. Methods: This was a prospective longitudinal study conducted at nine health facilities in Uganda. Persons with AHD (CD4 < 200 cells/mm Results: We enrolled 332 participants with AHD, and 66.6% were newly diagnosed with HIV. Over half were female (51.5%), with a median age of 35 years (interquartile range [IQR] = 29-42) for all participants. The median CD4 T-cell count was 73 cells/µL (IQR = 30.5-126.5). Eight (2.4%) participants were diagnosed with probable histoplasmosis. None of the cases received the recommended antifungals because they were not available in the country. After 2 years, 5 cases were still alive, 2 were lost to follow-up, and 1 died. Major challenges included missed diagnosis, low index of clinical suspicion, overlap of symptoms with those of pulmonary TB, high cost, limited access to antifungals such as voriconazole and itraconazole, radiology and laboratory investigations, and lack of knowledge about treatment guidelines. Conclusions: Histoplasmosis occurs at a low frequency among persons with AHD in Uganda. Numerous challenges hinder a definite diagnosis and treatment. However, despite these challenges, survival among persons with AHD in Uganda who have untreated histoplasmosis is relatively good.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.